Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q6N021: Variant p.Asp1242Arg

Methylcytosine dioxygenase TET2
Gene: TET2
Feedback?
Variant information Variant position: help 1242 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Aspartate (D) to Arginine (R) at position 1242 (D1242R, p.Asp1242Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help Requires 2 nucleotide substitutions. Any additional useful information about the variant.


Sequence information Variant position: help 1242 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 2002 The length of the canonical sequence.
Location on the sequence: help EAAVIVILILVWEGIPLSLA D KLYSELTETLRKYGTLTNRR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         EAAVIVILILVWEGIPLSLADKLYSELTETLRKYGTLTNRR

Mouse                         ETAVMVIAIMLWDGIPKLLASELYSELTDILGKCGICTNRR

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 2002 Methylcytosine dioxygenase TET2
Binding site 1261 – 1261
Alternative sequence 1166 – 2002 Missing. In isoform 2.
Alternative sequence 1195 – 2002 Missing. In isoform 3.
Mutagenesis 1261 – 1261 R -> G. Loss of enzyme activity.
Mutagenesis 1262 – 1262 R -> A. Slightly reduces enzyme activity.
Helix 1238 – 1255



Literature citations
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
Tefferi A.; Pardanani A.; Lim K.H.; Abdel-Wahab O.; Lasho T.L.; Patel J.; Gangat N.; Finke C.M.; Schwager S.; Mullally A.; Li C.-Y.; Hanson C.A.; Mesa R.; Bernard O.; Delhommeau F.; Vainchenker W.; Gilliland D.G.; Levine R.L.;
Leukemia 23:905-911(2009)
Cited for: INVOLVEMENT IN MYELOPROLIFERATIVE DISORDERS; VARIANTS ARG-1242 AND THR-1873;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.